Sanofi-Aventis S.A. ADR (SNY) Stock Price, Quote & News

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 33 1 53 77 40 00

Website: www.sanofi.com

Address:

46, avenue de la Grande Armée, Paris, France

BioRich Oct. 25 at 5:10 AM

$ALT Thanks to Mr. 32K Shares for trying to pump $SNY as hopeful suitor showing pity on the dying quail, ALT. It motivated to use this boards favorite tool (AI) and ask: "If Sanofi were to buy a MASH company, who would they buy?" Answer: 1) $MDGL 2) $IVA 3) $IONS My pick is $IVA. I think a deal is done and they are just waiting for the ink to dry. Sorry ALT Nation, no mention of $ALT. Not for buyout. Not for partnership. Not for licensing. ChatGPT didn't even acknowledge $ALT was a player when it listed off other potential candidates.

0 · Reply

ZacksResearch Oct. 24 at 4:50 PM

$SNY beats again — Dupixent is carrying the load 💪 Q3 earnings topped forecasts as Dupixent surged past EUR 4B in sales, more than making up for softness in the vaccine segment. Full breakdown here 👉 https://www.zacks.com/stock/news/2776468/sanofi-q3-earnings-beat-dupixent-drives-growth-as-vaccines-decline?cid=sm-stocktwits-2-2776468-teaser-17564&ADID=SYND_STOCKTWITS_TWEET_2_2776468_TEASER_17564

0 · Reply

smartoptionstrader Oct. 24 at 4:37 PM

MAIN POST: Big Pharma's M&A wave isn't slowing—it's accelerating into 2026. $MRK $JNJ $SNY desperately plugging patent cliff revenue holes. But here's the smarter play: $GS collects fees on every deal. Trading at $781 (15.5x earnings, below $SPY average) and $44 off September highs, Goldman is positioned perfectly. Lower rates, desperate acquirers, and frozen IPOs lead to more deals, resulting in more GS fees. Don't gamble on which biotech gets bought—follow the money to Wall Street's M&A king. Goldman Sachs Long-Term Price Chart (1997-2025) - Shows a steady upward trajectory with a September 2025 record high at $825, currently trading at $781. The chart demonstrates GS's consistent performance across multiple market cycles, validating the bullish technical setup with clear upside potential to new highs.

0 · Reply

ZacksResearch Oct. 24 at 3:50 PM

$SNY beats Q3 expectations — but why isn't the stock soaring? 🤔 Sanofi's Q3 results showed a 13.2% EPS increase at constant currency, beating the Zacks Consensus Estimate with Dupixent sales hitting over €4B for the first time. Yet, shares are only up 2% in pre-market trading. Discover why the market's lukewarm on SNY despite strong performance 👉 https://www.zacks.com/stock/news/2776468/sanofi-q3-earnings-beat-dupixent-drives-growth-as-vaccines-decline?cid=sm-stocktwits-2-2776468-body-17553&ADID=SYND_STOCKTWITS_TWEET_2_2776468_BODY_17553

0 · Reply

Diapers_Tequila Oct. 24 at 3:25 PM

$ALT Here is the link for the $SNY call this morning for everyone who missed it. https://www.youtube.com/watch?v=o6p0W4ZsLXw

2 · Reply

Jacked_Nicholson Oct. 24 at 1:53 PM

$ALT @Designed2Gain $SNY $ €14-€15B

3 · Reply

GreenEnergy2022 Oct. 24 at 1:26 PM

$ALT Sounds like $SNY is looking for a best in class investment

1 · Reply

BTC321 Oct. 24 at 12:53 PM

$NVAX $NVAX $SNY 🚀 Sanofi just reported strong positive results and mentioned Novavax in the same breath. The combo vaccines Fluzone HD + Nuvaxovid and Flublok + Nuvaxovid are already on the FDA Fast Track (US). 👉 If approved, this would be the first flu + COVID-19 protein vaccine — a potential game changer for both companies. Momentum is building. Volume next. 💥 #NVAX #SNY #FastTrack #Biotech #ShortSqueeze

1 · Reply

OpenOutcrier Oct. 24 at 12:37 PM

$SNY (+2.1% pre) Sanofi (SNY) Tops Q3 EPS by 72c https://ooc.bz/l/81768

0 · Reply

Quantumup Oct. 24 at 11:26 AM

H.C. Wainwright reiterated $CDTX Buy/$150 after at the European Scientific Working Group on Influenza (ESWI)s 10th Influenza Conference, Cidara presented translational efficacy data on CD388, the company's lead influenza drug-Fc conjugate (DFC) candidate. $SNY $JNJ HCW in its note said:

0 · Reply

Sanofi: Is Dupixent Too Successful?

Oct 24, 2025, 1:37 PM EDT - 18 hours ago

Sanofi Q3: Cash-Rich, Cheap, And Loading 2026 Shots On Goal

Oct 24, 2025, 1:37 PM EDT - 18 hours ago

Sanofi (SAN:CA) Q3 2025 Earnings Call Transcript

SAN

Oct 24, 2025, 10:47 AM EDT - 21 hours ago

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark

Oct 24, 2025, 2:55 AM EDT - 1 day ago

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

Oct 24, 2025, 1:35 AM EDT - 1 day ago

Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged

Oct 24, 2025, 1:30 AM EDT - 1 day ago

Press release: Q3: continued sales and earnings progress

Oct 23, 2025, 1:00 AM EDT - 2 days ago

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Oct 22, 2025, 1:00 AM EDT - 3 days ago

Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Oct 20, 2025, 7:30 AM EDT - 5 days ago

Press Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program

Oct 20, 2025, 2:30 AM EDT - 5 days ago

Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors

Oct 20, 2025, 1:00 AM EDT - 5 days ago

Press Release: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

Oct 17, 2025, 7:05 AM EDT - 8 days ago

Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia

Oct 17, 2025, 7:00 AM EDT - 8 days ago

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease

Oct 16, 2025, 6:00 AM EDT - 9 days ago

EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi

Oct 13, 2025, 5:00 AM EDT - 12 days ago

ITM Appoints Annette Breunig as Chief People Officer

Oct 8, 2025, 8:00 AM EDT - 17 days ago

BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform

Oct 8, 2025, 1:00 AM EDT - 17 days ago

Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors

Oct 5, 2025, 5:09 AM EDT - 20 days ago

Sanofi: Undervalued 2026 Pipeline, And Solid Results (Rating Upgrade)

Oct 2, 2025, 8:00 AM EDT - 23 days ago

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

RVTY

Oct 1, 2025, 7:00 AM EDT - 24 days ago

QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials

Sep 26, 2025, 2:37 PM EDT - 4 weeks ago

A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff

AZN LLY NVO

Sep 26, 2025, 1:40 PM EDT - 4 weeks ago

Sanofi Expands Insulin Savings Program To Cover All US Patients

Sep 26, 2025, 8:26 AM EDT - 4 weeks ago

Sanofi to offer all insulin products for $35 per month in US

Sep 26, 2025, 8:00 AM EDT - 4 weeks ago

Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US

Sep 24, 2025, 8:49 AM EDT - 4 weeks ago

French court orders Sanofi to pay $177 million for anti-competitive behaviour

Sep 24, 2025, 1:05 AM EDT - 4 weeks ago

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation

Sep 24, 2025, 1:00 AM EDT - 4 weeks ago

Press release: Availability of the Q3 2025 Aide mémoire

Sep 23, 2025, 2:03 PM EDT - 4 weeks ago

Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript

SAN

Sep 23, 2025, 1:00 AM EDT - 4 weeks ago

Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1

Sep 22, 2025, 1:00 AM EDT - 4 weeks ago

Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis

Sep 22, 2025, 12:30 AM EDT - 4 weeks ago

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion

REGN

Sep 17, 2025, 1:00 AM EDT - 5 weeks ago

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study

Sep 11, 2025, 1:00 AM EDT - 6 weeks ago

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration

Sep 10, 2025, 1:03 PM EDT - 6 weeks ago

US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says

ABBV AZN GSK NVO NVS AMGN LLY

Sep 10, 2025, 8:00 AM EDT - 6 weeks ago

Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®

Sep 10, 2025, 1:00 AM EDT - 6 weeks ago

Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes

Sep 9, 2025, 4:40 PM EDT - 6 weeks ago

Sanofi (SNY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 2:56 PM EDT - 7 weeks ago

Sanofi market value tanks following weak results on eczema drug trials

Sep 4, 2025, 2:36 PM EDT - 7 weeks ago

Why Is Sanofi Stock Falling Thursday?

Sep 4, 2025, 9:21 AM EDT - 7 weeks ago

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

Sep 4, 2025, 4:43 AM EDT - 7 weeks ago

Sanofi Shares Sink as Experimental Drug Results Disappoint

Sep 4, 2025, 4:01 AM EDT - 7 weeks ago

Sanofi shares sink over 9% on weak trial results for experimental inflammation drug

Sep 4, 2025, 1:46 AM EDT - 7 weeks ago

Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial

Sep 4, 2025, 1:01 AM EDT - 7 weeks ago

Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Sep 3, 2025, 2:09 PM EDT - 7 weeks ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD JNJ LLY

Aug 30, 2025, 1:24 PM EDT - 7 weeks ago

Now Is The Time To Buy This High-Yielding Trio

AES CMCSA

Aug 29, 2025, 5:56 PM EDT - 2 months ago

US FDA approves Sanofi's drug for a rare blood disorder

Aug 29, 2025, 5:50 PM EDT - 2 months ago

Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia

Aug 14, 2025, 1:00 AM EDT - 2 months ago

Press Release: Sanofi's rilzabrutinib earns orphan designation in the EU for IgG4-related disease

BioRich Oct. 25 at 5:10 AM

0 · Reply

ZacksResearch Oct. 24 at 4:50 PM

0 · Reply

smartoptionstrader Oct. 24 at 4:37 PM

0 · Reply

ZacksResearch Oct. 24 at 3:50 PM

0 · Reply

Diapers_Tequila Oct. 24 at 3:25 PM

$ALT Here is the link for the $SNY call this morning for everyone who missed it. https://www.youtube.com/watch?v=o6p0W4ZsLXw

2 · Reply

Jacked_Nicholson Oct. 24 at 1:53 PM

$ALT @Designed2Gain $SNY $ €14-€15B

3 · Reply

GreenEnergy2022 Oct. 24 at 1:26 PM

$ALT Sounds like $SNY is looking for a best in class investment

1 · Reply

BTC321 Oct. 24 at 12:53 PM

1 · Reply

OpenOutcrier Oct. 24 at 12:37 PM

$SNY (+2.1% pre) Sanofi (SNY) Tops Q3 EPS by 72c https://ooc.bz/l/81768

0 · Reply

Quantumup Oct. 24 at 11:26 AM

0 · Reply

Elevate1 Oct. 24 at 11:09 AM

$SNY

0 · Reply

cubie Oct. 23 at 7:58 PM

EARNINGS Before Bell SO PYB: $PG 140-$142S or 160-162S $GD 320 or 360 $HCA $400 OR 470 $ITW 240 or 270 $SNY 45s or 54s-$55

0 · Reply

Ersttr3der Oct. 23 at 6:38 PM

$DECK playing deck then $SNY ER!

0 · Reply

27R Oct. 23 at 4:21 PM

$SNY Earnings release at before tomorrow open, significant post-earnings volatility with relatively reasonable implied volatility, perhaps consider a Straddle

0 · Reply

Gemini367 Oct. 23 at 12:27 PM

$VTYX Congrats to all, who are still invested. $10 on deck. With yesterdays news, buyout potential by $SNY and other big pharma players. Best of luck.

0 · Reply

clan Oct. 22 at 7:39 PM

$MNKD How 'bout a deep dive on ULTRA Rapid-Acting mealtime insulin? None exists by $LLY $NVO nor $SNY , just by MannKind. #Afrezza

0 · Reply

ZacksResearch Oct. 22 at 3:01 PM

Breakthrough alert: $SNY just hit all key endpoints in its rare disease trial 🚀 Efdoralprin alfa met every primary goal in a global phase II study — positioning it as a potential first restorative recombinant therapy for AATD. Full story on what this means for Sanofi’s pipeline 👉 https://www.zacks.com/stock/news/2774232/snys-efdoralprin-alfa-meets-key-endpoints-in-rare-disease-study?cid=sm-stocktwits-2-2774232-teaser-17070&ADID=SYND_STOCKTWITS_TWEET_2_2774232_TEASER_17070

0 · Reply

ZacksResearch Oct. 22 at 2:01 PM

$SNY's efdoralprin alfa could revolutionize AATD treatment! 🚀 The phase II ElevAATe study met all primary and key secondary endpoints, showing significant improvements in functional AAT levels over current therapies. With FDA fast track and orphan drug designations, this candidate is one to watch. See what this means for Sanofi and AATD patients 👉 https://www.zacks.com/stock/news/2774232/snys-efdoralprin-alfa-meets-key-endpoints-in-rare-disease-study?cid=sm-stocktwits-2-2774232-body-17052&ADID=SYND_STOCKTWITS_TWEET_2_2774232_BODY_17052

0 · Reply

Quantumup Oct. 21 at 7:20 PM

Mizuho y'day🏁 $CLDX Outperform/$48 $NVS $REGN - $SNY JSPR $LLY TEVA ALLK Mizuho said: We are initiating coverage of Celldex Therapeutics with an Outperform rating and $48 PT as we see barzovolimab (anti-KIT mAb) as positioned to play a significant role in mast-cell mediated diseases, namely chronic urticaria. We believe barzolvolimab has potential to establish best-in-class efficacy among the increasingly competitive landscape, offering the deepest and most sustained clinical benefit. With this, we performed probability modeling that we believe points to high probability of future statistical success in the ongoing Phase III trials for all-comers and the important subgroup of omalizumab-experienced patients, as well as clear opportunity to generate a best-in-indication efficacy profile. Altogether, we project $2.X.6B in risk-adjusted 2035 WW sales for barzolvolimab in chronic urticaria and expect positive Phase III data, as well as potential indication expansion to drive outperformance.

0 · Reply

Quantumup Oct. 20 at 6:46 PM

Piper Sandler reiterated $UPB Overweight-$75 and said UPB has traded up ~130%+ over the last 6-months where verekitug (TSLP-R mAb) showed compelling efficacy/safety in Ph2 VIBRANT CRSwNP with upcoming Ph2 VALIANT severe asthma topline 1Q26 (~Feb/Mar 2026, per our math). $AMGN - $AZN $REGN - $SNY Piper Sandler added:

0 · Reply

HahaYouSUCK Oct. 20 at 12:47 PM

$COGT $BPMC $SNY we coming for the belt

0 · Reply

Thestocktraderhubzee Oct. 20 at 10:02 AM

WATCHLIST OCT 20 2025 $NVO FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event $SNY AlphaMedix Shows Durable, Clinically Meaningful Responses In Advanced GEP-NETs, Meeting All Primary Endpoints In Phase 2 Study $IOBT IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance $PHAR Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases $STM STMicroelectronics Introduces Four New 5MP BrightSense Image Sensors For Industrial Automation, Security, And Smart Retail Applications

0 · Reply

Market Cap	121.60B
Revenue (ttm)	47.92B
Net Income (ttm)	6.02B
EPS (ttm)	N/A
PE Ratio	12.16
Forward PE	11.13
Profit Margin	12.55%
Debt to Equity Ratio	0.29

Volume	4,635,000
Avg Vol	3,275,164
Day's Range	N/A - N/A
Shares Out	2.46B
Stochastic %K	85%
Beta	0.51
Analysts	Strong Sell
Price Target	$62.94